Table 3.
Cost effectiveness by accounting convention
| NICE convention | Social costs, undiscounted benefits | |
|---|---|---|
| Immediate treatment v surveillance: | ||
| Nominal ICER (£ per QALY) | 4546 | 7378 |
| Uncertainty analysis: | ||
| Higher costs (%) | 81.0 | 83.7 |
| Higher benefits (%) | 51.9 | 52.1 |
| Acceptable ICER (%) | 51.1 | 50.5 |
| 95% CIs for ICER (£) | −11 375 to 11 109 | −22 977 to 23 262 |
| Biopsy and recall v immediate treatment: | ||
| Nominal ICER (£ per QALY) | 26 | −370 |
| Uncertainty analysis: | ||
| Higher costs (%) | 47.9 | 44.1 |
| Higher benefits (%) | 53.9 | 56.2 |
| Acceptable ICER (%) | 53.4 | 55.4 |
| 95% CIs for ICER (£) | −9390 to 9858 | −18 698 to 21 344 |
| Biopsy and recall v surveillance: | ||
| Nominal ICER (£ per QALY) | 1764 | 2373 |
| Uncertainty analysis: | ||
| Higher costs (%) | 80.5 | 80.9 |
| Higher benefits (%) | 55.1 | 59.1 |
| Acceptable ICER (%) | 54.3 | 57.4 |
| 95% CIs for ICER (£) | −12 989 to 11 196 | −24 651 to 25 770 |
ICER=incremental cost effectiveness ratio; QALY=quality adjusted life year.